All News

Despite telehealth’s rise in popularity during the height of COVID-19, many individuals still aren't aware that it's a viable option.

Out of an abundance of caution, the infant formula giant has recalled one of their powdered infant formula products because of a potentially dangerous bacteria.

The company also will establish a $35 out-of-pocket price cap for for all patients with commercial insurance that use Latnus

There was a lower probability of initiating psycholeptics and experiencing postpartum psychiatric emergencies in study patients who continued using antidepressants

Your weekly roundup of the latest news from Drug Topics®.

Polio prevalence has been reduced by 99.99% in the past 35 years. But the disease continues to exist in countries like Pakistan and Afghanistan, where it seeds outbreaks elsewhere.

A combination of dabrafenib with trametinib was approved by the FDA for treatment of pediatric patients 1 year and older with low-grade glioma & BRAF V600E mutation who require systemic therapy.

The vaccine, developed by GSK, is "very encouraging" step in fight to treat meningococcal disease

Treating myelofibrosis with Jakafi earlier has shown promise in improving both survival and symptom burden

Drug Topics will continue to update this story as new information becomes available.

A new booster shot of the Pfizer-BioNTech COVID-19 vaccine is now available for children aged 6 months to 4 years, in an effort to continue to curb the effects of COVID-19

Results from a phase 3 study show that the drug is effective in treating VMS symptoms due to menopause.

Per VA regulations, anyone who has had a stroke or seizure within the last year, as well as those with MRIs showing microhemmorrhages, aneurysms, lesions or tumors would be excluded from coverage of the drug, called Leqambi

How are hiring trends shaping up for the future of health care?

The product, called Lenire, uses bimodal stimulation and will be available in April 2023

According to a company press release, the price reductions will go into effect at the start of 2024

The President said he will make Medicare “solvent beyond 2050 without cutting a penny in benefits.”

The spray, called Zavzpret, intends to help individuals who struggle with migraines but can't take oral medication because of nausea or vomiting

Critics of PBM's say that the high number of exclusions narrows patient options and make medications financially inaccessible.

Your weekly roundup of the latest news from Drug Topics®.

The drug, called Makena, was intended to stop premature births, but has not been effective in its goal, says the FDA.

The FDA agreed to review a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.

Voxzogo is already available for patients over 5 years with a genetic cause of dwarfism. The PDUFA date is set for Oct. 21, 2023, and will potentially expand the drug to children 5 and under.

The drug, manufactured by Sandoz, will treat conditions including osteoporosis in postmenopausal women

Results of an analysis of the VOYAGER PAD clinical trial were presented at ACC.23.

A single oral dose of azithromycin during labor in women planning vaginal delivery can significantly reduce the risk of maternal sepsis or death

The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.

The safety of gel manicures is under renewed scrutiny after a new study suggested they can cause DNA damage